Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modulatory Effect of Prodigiosin or Pioglitazone on Tumor Immune Microenvironment and the Crosstalk to Immune-Checkpoint Protein(s)

NCT06502249 is registered in ClinicalTrials.gov with Ain Shams University as lead sponsor.

NCT NCT06502249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06502249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modulatory Effect of Prodigiosin or Pioglitazone on Tumor Immune Microenvironment and the Crosstalk to Immune-Checkpoint Protein(s)
Lead sponsor
Ain Shams University
Phase
Observational
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
September 30, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, nsclc